ClinicalTrials.Veeva

Menu

Safety Study of Nebivolol for COPD Patients

The University of Chicago logo

The University of Chicago

Status and phase

Withdrawn
Phase 3
Phase 2

Conditions

High Blood Pressure

Treatments

Drug: Nebivolol
Drug: Placebo

Study type

Interventional

Funder types

Other
Industry

Identifiers

NCT01939990
11-0720

Details and patient eligibility

About

The purpose of this study is to demonstrate the safety and effectiveness of the study drug Nebivolol, in people who suffer with high blood pressure with Chronic Obstructive Pulmonary Disease (COPD).

Full description

The study would be a randomized, placebo-controlled trial of 60 hypertensive patients with documented COPD greater than age 40.

Sex

All

Ages

40 to 75 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Clinical diagnosis of high blood pressure and chronic obstructive pulmonary disease (COPD)

Exclusion criteria

  • Asthma; Heart failur;
  • End stage kidney disease;
  • acute myocardial infarction,unstable angina, stroke or TIA within the past year;
  • Females who are pregnant, lactating or women of childbearing potential who are not using approved method of contraception.

Trial design

Primary purpose

Health Services Research

Allocation

Randomized

Interventional model

Parallel Assignment

Masking

Double Blind

0 participants in 2 patient groups, including a placebo group

Nebivolol
Active Comparator group
Description:
Group A will be given Nebivolol 5 to 10mg per day
Treatment:
Drug: Nebivolol
Placebo
Placebo Comparator group
Description:
Group B will be given Placebo.
Treatment:
Drug: Placebo

Trial contacts and locations

1

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2025 Veeva Systems